In a single-arm phase 2 study (ClinicalTrials.gov Identifier: NCT01591733), researchers enrolled 50 previously untreated patients with newly diagnosed and borderline resectable pancreatic cancer. Patients were treated with 8 cycles of neoadjuvant FOLFIRINOX, and if there was no evidence of vascular involvement during restaging, patients received a short course of chemoradiotherapy; patients whose vascular involvement was not resolved received a longer course of chemoradiotherapy. Surgery was performed 1 to 3 weeks after the completion of radiotherapy. The median follow-up was 18 months. Read more . . .